Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• T-cell malignancies are aggressive cancers with poor patient prognosis.
• Current immunotherapies, like CD19 CAR T cells, show promise but face challenges in T-cell malignancies.
• Targeting shared antigens in T-cell malignancies requires careful consideration of T-cell depletion.

Purpose of the Study:

• To evaluate the potential of CD5 Chimeric Antigen Receptor (CAR) T cells as a novel immunotherapy for T-cell malignancies.
• To investigate the biological properties, efficacy, and safety of various CD5 CAR constructs.
• To explore the impact of a CD52 safety switch on CAR T-cell persistence and function.

Main Methods:

• Development and evaluation of multiple CD5 CAR constructs.
• In vitro testing of CD5 CAR T cells against malignant T-cell lines and primary tumors.
• Construction and analysis of three murine models to assess CD5 down-regulation, CAR efficacy, specificity, and safety switch modulation.

Main Results:

• CD5 CAR T cells demonstrated specific and potent lysis of malignant T-cell targets in vitro.
• Significant control of tumor growth and improved survival were observed in vivo using xenograft models of T-acute lymphoblastic leukemia (T-ALL).
• Evaluation of different CD5 CAR designs and the incorporation of a CD52 safety switch provided insights into modulating CAR T-cell behavior.

Conclusions:

• CD5 CAR T-cell therapy holds significant potential for treating T-cell malignancies.
• These findings support the further clinical investigation of CD5 CAR T cells for refractory T-cell cancers.
• The study highlights the feasibility of targeting CD5 while considering safety and functional modulation strategies.